

Special Issue

Vaccine-Induced Immune Thrombotic Thrombocytopenia

Message from the Guest Editors

We are releasing a Special Issue of *Vaccines* on vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare adverse event following immunization (AEFI) associated with COVID-19 vaccines. We aim to deepen our understanding of VITT and welcome submissions on mechanisms, clinical manifestations, diagnostic criteria, and management strategies. The Special Issue is open for submissions until 30 September 2024. Accepted manuscripts will contribute to our understanding of VITT, benefiting healthcare professionals, researchers, and policymakers in making informed decisions. Thank you for your contributions.

Guest Editors

Dr. Doris F. Oberle

Department of Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany

Dr. Linda Schönborn

Institute for Transfusion Medicine, University Hospital Greifswald, 17487 Greifswald, Germany

Deadline for manuscript submissions

closed (31 March 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/192822

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).